Pykus Therapeutics
James (Tony) Stefater has a strong background in the medical field, with work experience in both the business and surgical aspects of ophthalmology. In 2016, they co-founded Pykus Therapeutics and served as the President. Their leadership skills and entrepreneurial mindset contributed to the success of the company. In 2019, they joined Ophthalmic Consultants of Boston as a Vitreoretinal Surgeon, where they continue to apply their surgical expertise in the field of ophthalmology. James (Tony) Stefater's career showcases their dedication to advancing the field of ophthalmology through business ventures and surgical practice.
James (Tony) Stefater's education history is as follows: they earned a Bachelor of Science (B.S.) degree in Biochemistry and Molecular Biology from Centre College. James (Tony) then attended the University of Cincinnati, where they obtained both a Doctor of Medicine (M.D.) degree and a Doctor of Philosophy (Ph.D.) degree in Molecular and Developmental Biology. After that, they attended Harvard Medical School and completed an internship in Internal Medicine. James (Tony) subsequently completed a residency in Ophthalmology at Harvard Medical School. Finally, they pursued further specialization by completing a fellowship in Vitreoretinal Surgery at Harvard Medical School.
This person is not in any teams
Pykus Therapeutics
Pykus Therapeutics, Inc. was founded in 2016 to develop a dissolvable intraocular surgical device to make retinal surgery less painful and more successful.The co-founders were ophthalmology residents at the Massachusetts Eye and Ear Infirmary and Harvard Medical School when they developed a novel hydrogel to replace the use of intraocular gasduring retinal surgery. This innovation will eliminate the extreme burden placed on patients including the requirement for face-down positioning, inability to see for weeks, and inability to fly for weeks.